“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day. We recently compiled a list of the Top 11 CRISPR ...

The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...